What one share of CytoSorbents holds
We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
CytoSorbents’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.30 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.15 |
| Cash and investments | $0.07 |
| Debt | $0.27 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$1.25 | $0.03 | −$0.64 | — | −$1.64 |
| 2011 | $0.01 | −$1.25 | $0.01 | −$0.60 | — | −$1.42 |
| 2012 | $0.17 | −$0.75 | $0.00 | −$0.46 | — | −$1.35 |
| 2013 | $0.26 | −$0.75 | $0.00 | −$0.37 | — | −$1.42 |
| 2014 | $0.29 | −$1.29 | $0.01 | −$0.47 | — | $0.30 |
| 2015 | $0.19 | −$0.38 | $0.02 | −$0.38 | — | $0.39 |
| 2016 | $0.37 | −$0.46 | $0.01 | −$0.27 | — | $0.05 |
| 2017 | $0.55 | −$0.32 | $0.04 | −$0.27 | — | $0.35 |
| 2018 | $0.73 | −$0.56 | $0.02 | −$0.37 | — | $0.53 |
| 2019 | $0.77 | −$0.60 | $0.02 | −$0.54 | — | $0.10 |
| 2020 | $1.06 | −$0.20 | $0.02 | −$0.16 | — | $1.83 |
| 2021 | $1.00 | −$0.57 | $0.08 | −$0.41 | — | $1.43 |
| 2022 | $0.80 | −$0.75 | $0.14 | −$0.79 | — | $0.81 |
| 2023 | $0.70 | −$0.65 | $0.01 | −$0.50 | — | $0.43 |
| 2024 | $0.65 | −$0.38 | $0.01 | −$0.27 | — | $0.20 |
| 2025 | $0.60 | −$0.13 | $0.00 | −$0.20 | — | $0.09 |
Common questions about CytoSorbents
How much does one share of CytoSorbents earn?
Over the last 12 months, CytoSorbents lost $0.30 for each share.
Does CytoSorbents pay a dividend?
CytoSorbents didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is CytoSorbents’s book value per share?
CytoSorbents’s book value is negative (−$0.01 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of CytoSorbents have?
Each share of CytoSorbents has $0.07 of cash and investments and $0.27 of debt, as of June 30, 2026.
What is CytoSorbents’s free cash flow per share?
−$0.15 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has CytoSorbents bought back shares?
CytoSorbents’s share count rose about 1429% from 2010 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.